Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire & Baxalta Seal The Deal

Executive Summary

Shire PLC and Baxalta Inc. shareholders have both voted in favor of the latter's sale to rare disease focused Shire for a price tag of $32bn – closing an almost year-long deal discussion.

Advertisement

Related Content

Stockwatch: Mistaken Acquisitions Dim Earnings Season
Scrip's Pharma Influencers Of 2016
Shire's Ornskov: The Modest Pediatrician With Fierce Corporate Ambition
Shire’s Ornskov Says Baxalta Integration on Track, Ups Synergies Forecast
Shire's Ornskov Maps Out Future Prospects Post- Baxalta Merger

Topics

Advertisement
UsernamePublicRestriction

Register

SC065297

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel